Cripto‐1 (CR‐1) is related to the biological behaviour and prognosis of carcinomas. The purpose of this study was to investigate the significance of CR‐1 expression in surgically resected stage I non‐small cell lung cancer (NSCLC). One hundred and forty‐eight patients with completely resected stage I NSCLC and available clinical follow‐up data were assessed. The protein expression of CR‐1 in the tumours was detected by immunohistochemistry. CR‐1 was highly expressed in 64 of 148 tumours. Among patients with high CR‐1 expression, progression‐free survival and overall survival rate were significantly lower than those of patients with low CR‐1 levels (P = .013 and P = .019, respectively). The incidence of distant metastasis in patients with high CR‐1 expression was significantly higher than that of in patients with low CR‐1 expression (57.13% vs 21.43%, P = .001). The results of the multivariate analysis confirmed that a high CR‐1 was a significant factor for poor prognosis. In conclusion, CR‐1 could be a useful prognostic factor in patients with stage I NSCLC, likely as an indicator of the metastatic propensity of the tumour.

中文翻译：

---

Cripto-1的表达预示了I期非小细胞肺癌的预后不良。

Cripto-1（CR-1）与癌症的生物学行为和预后有关。这项研究的目的是调查在外科切除的I期非小细胞肺癌（NSCLC）中CR-1表达的重要性。评估了148例完全切除的I期NSCLC患者和可用的临床随访数据。通过免疫组织化学检测CR-1在肿瘤中的蛋白表达。148个肿瘤中有64个肿瘤高表达了CR-1。在CR-1表达高的患者中，无进展生存期和总生存率显着低于CR-1水平低的患者（P  = .013和P 分别为.019）。CR-1高表达患者远处转移的发生率明显高于CR-1低表达患者（57.13％对21.43％，P  = .001）。多元分析的结果证实，高CR-1是不良预后的重要因素。总之，CR-1对I期非小细胞肺癌患者可能是有用的预后因素，可能是肿瘤转移倾向的指标。